Background: Increased omega-3 (n-3) fatty acid consumption is reported to benefit patients with metabolic syndrome, possibly due to improved adipose tissue function.Objective: We tested the effects of high-dose, very-long-chain ω-3 fatty acids on adipose tissue inflammation and insulin regulation of lipolysis.Design: A double-blind, placebo-controlled study compared 6 mo of 3.9 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)/d (4.2 g total ω-3/d; n = 12) with a placebo (4.2 g oleate/d; n = 9) in insulin-resistant adults. Before and after treatment, the volunteers underwent adipose tissue biopsies to measure the total (CD68+), pro- (CD14+ = M1), and anti- (CD206+ = M2) inflammatory macrophages, crown-like structures, and senescent cells, as well as a 2-step pancreatic clamping with a [U-13C]palmitate infusion to determine the insulin concentration needed to suppress palmitate flux by 50% (IC50(palmitate)f). Results: In the ω-3 group, the EPA and DHA contributions to plasma free fatty acids increased (P = 0.0003 and P = 0.003, respectively), as did the EPA and DHA content in adipose tissue (P < 0.0001 and P < 0.0001, respectively). Despite increases in adipose and plasma EPA and DHA in the ω-3 group, there were no significant changes in the IC50(palmitate)f (19 ± 2 compared with 24 ± 3 μIU/mL), adipose macrophages (total: 31 ± 2/100 adipocytes compared with 33 ± 2/100 adipocytes; CD14+: 13 ± 2/100 adipocytes compared with 14 ± 2/100 adipocytes; CD206+: 28 ± 2/100 adipocytes compared with 29 ± 3/100 adipocytes), crown-like structures (1 ± 0/10 images compared with 1 ± 0/10 images), or senescent cells (4% ± 1% compared with 4% ± 1%). There were no changes in these outcomes in the placebo group.Conclusions: Six months of high-dose ω-3 supplementation raised plasma and adipose ω-3 fatty acid concentrations but had no beneficial effects on adipose tissue lipolysis or inflammation in insulin-resistant adults. This trial was registered at clinicaltrials.gov as NCT01686568.
RCT Entities:
Background: Increased omega-3 (n-3) fatty acid consumption is reported to benefit patients with metabolic syndrome, possibly due to improved adipose tissue function.Objective: We tested the effects of high-dose, very-long-chain ω-3 fatty acids on adipose tissue inflammation and insulin regulation of lipolysis.Design: A double-blind, placebo-controlled study compared 6 mo of 3.9 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)/d (4.2 g total ω-3/d; n = 12) with a placebo (4.2 g oleate/d; n = 9) in insulin-resistant adults. Before and after treatment, the volunteers underwent adipose tissue biopsies to measure the total (CD68+), pro- (CD14+ = M1), and anti- (CD206+ = M2) inflammatory macrophages, crown-like structures, and senescent cells, as well as a 2-step pancreatic clamping with a [U-13C]palmitate infusion to determine the insulin concentration needed to suppress palmitate flux by 50% (IC50(palmitate)f). Results: In the ω-3 group, the EPA and DHA contributions to plasma free fatty acids increased (P = 0.0003 and P = 0.003, respectively), as did the EPA and DHA content in adipose tissue (P < 0.0001 and P < 0.0001, respectively). Despite increases in adipose and plasma EPA and DHA in the ω-3 group, there were no significant changes in the IC50(palmitate)f (19 ± 2 compared with 24 ± 3 μIU/mL), adipose macrophages (total: 31 ± 2/100 adipocytes compared with 33 ± 2/100 adipocytes; CD14+: 13 ± 2/100 adipocytes compared with 14 ± 2/100 adipocytes; CD206+: 28 ± 2/100 adipocytes compared with 29 ± 3/100 adipocytes), crown-like structures (1 ± 0/10 images compared with 1 ± 0/10 images), or senescent cells (4% ± 1% compared with 4% ± 1%). There were no changes in these outcomes in the placebo group.Conclusions: Six months of high-dose ω-3 supplementation raised plasma and adipose ω-3 fatty acid concentrations but had no beneficial effects on adipose tissue lipolysis or inflammation in insulin-resistant adults. This trial was registered at clinicaltrials.gov as NCT01686568.
Authors: A A Rivellese; A Maffettone; C Iovine; L Di Marino; G Annuzzi; M Mancini; G Riccardi Journal: Diabetes Care Date: 1996-11 Impact factor: 19.112
Authors: Evan M Hill; Raymond M Esper; Ananda Sen; Becky R Simon; Muhammad N Aslam; Yan Jiang; Michael K Dame; Shannon D McClintock; Justin A Colacino; Zora Djuric; Max S Wicha; William L Smith; Dean E Brenner Journal: J Nutr Biochem Date: 2019-05-24 Impact factor: 6.048
Authors: Ayca Gucalp; Xi K Zhou; Elise D Cook; Judy E Garber; Katherine D Crew; Julie R Nangia; Priya Bhardwaj; Dilip D Giri; Olivier Elemento; Akanksha Verma; Hanhan Wang; J Jack Lee; Lana A Vornik; Carrie Mays; Diane Weber; Valerie Sepeda; Holly O'Kane; Margaret Krasne; Samantha Williams; Patrick G Morris; Brandy M Heckman-Stoddard; Barbara K Dunn; Clifford A Hudis; Powel H Brown; Andrew J Dannenberg Journal: Cancer Prev Res (Phila) Date: 2018-02-16
Authors: Danyelle M Liddle; Amber L Hutchinson; Hannah R Wellings; Krista A Power; Lindsay E Robinson; Jennifer M Monk Journal: Nutrients Date: 2017-11-27 Impact factor: 5.717
Authors: Carol J Fabian; Christie A Befort; Teresa A Phillips; Jennifer L Nydegger; Amy L Kreutzjans; Kandy R Powers; Trina Metheny; Jennifer R Klemp; Susan E Carlson; Debra K Sullivan; Carola M Zalles; Erin D Giles; Stephen D Hursting; Jinxiang Hu; Bruce F Kimler Journal: Cancer Prev Res (Phila) Date: 2021-07-09
Authors: Michael I McBurney; Jeffrey B Blumberg; Rebecca B Costello; Manfred Eggersdorfer; John W Erdman; William S Harris; Elizabeth J Johnson; Susan Hazels Mitmesser; Robert C Post; Deshanie Rai; Leon J Schurgers Journal: Nutrients Date: 2021-05-28 Impact factor: 5.717